Systematic review: Adherence issues in the treatment of ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 23, Issue 5, 2006, Pages 577-585

  Kane, S V ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENEMA; MESALAZINE; PLACEBO; SALAZOSULFAPYRIDINE; SPD 476;

BLOATING; CANCER RISK; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; HEALTH CARE COST; HUMAN; LIFE SATISFACTION; LONG TERM CARE; MORBIDITY; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RELAPSE; REVIEW; SYSTEMATIC REVIEW; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADMINISTRATION, RECTAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ATTITUDE TO HEALTH; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; COST OF ILLNESS; DRUG ADMINISTRATION SCHEDULE; HEALTH CARE COSTS; HUMANS; MESALAMINE; PATIENT COMPLIANCE; QUALITY OF LIFE; RECURRENCE;

EID: 33644995445     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.02809.x     Document Type: Review

References (59)

1. Ardizzone S Ulcerative Colitis. Orphanet Encylcopedia 2003 Available at:. Last accessed November 2005
2. Schmidt C Stallmach A Etiology and pathogenesis of inflammatory bowel disease Minerva Gastroenterol Dietol 2005 51 127 45
3. Kovvali G Das KM Molecular mimicry may contribute to pathogenesis of ulcerative colitis FEBS Lett 2005 579 2261 6
4. Wen Z Fiocchi C Inflammatory bowel disease: autoimmune or immune-mediated pathogenesis Clin Dev Immunol 2004 11 195 204
5. Sutherland L MacDonald JK Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis Cochrane Database Syst Rev 2003 CD000543
6. Sutherland L Roth D Beck P May G Makiyama K Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis Cochrane Database Syst Rev 2002 CD000544
7. Cramer JA A systematic review of adherence with medications for diabetes Diabetes Care 2004 27 1218 24
8. Murphy DA Sarr M Durako SJ Moscicki A-B Wilson CM Muenz LR Barriers to HAART adherence among human immunodeficiency virus-infected adolescents Arch Pediatr Adolesc Med 2003 157 249 55
9. Loghman-Adham M Medication noncompliance in patients with chronic disease: issues in dialysis and renal transplantation Am J Manag Care 2003 9 155 71
10. Peura D Helicobacter pylori: rational management options Am J Med 1998 105 424 30
11. DiMatteo MR Giordani PJ Lepper HS Croghan TW Patient adherence and medical treatment outcomes: a meta-analysis Med Care 2002 40 794 811
12. World HO Adherence to Long-term Therapies. Evidence for Action 2003. Available at:, accessed July 2005.q4
13. Rudd P Clinicians and patients with hypertension: unsettled issues about compliance Am Heart J 1995 130 572 9
14. Morris AD Brennan GM MacDonald TM Donnan PT Population-based adherence to prescribed medication in type 2 diabetes: a cause for concern Diabetes 2000 49 Suppl 1 A76
15. Farup P Hinterleitner T Lukas M et al. Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis Inflamm Bowel Dis 2001 7 237 42
16. Hanauer SB Sninsky CA Robinson M et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis: a randomized, placebo-controlled trial Ann Intern Med 1996 124 204 11
17. Prantera C Viscido A Biancone L et al. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx Inflamm Bowel Dis 2005 11 421 7
18. Kane SV Cohen RD Aikens JE Hanauer SB Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis Am J Gastroenterol 2001 96 2929 33
19. Kane S Huo D Aikens J Hanauer S Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis Am J Med 2003 114 39 43
20. Levy RL Feld AD Increasing patient adherence to gastroenterology treatment and prevention regimens Am J Gastroenterol 1999 94 1733 42
21. Shale MJ Riley SA Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease Aliment Pharmacol Ther 2003 18 191 8
22. van Hees PA van Tongeren JH Compliance to therapy in patients on a maintenance dose of sulfasalazine J Clin Gastroenterol 1982 4 333 6
23. Sewitch MJ Abrahamowicz M Barkun A et al. Patient nonadherence to medication in inflammatory bowel disease Am J Gastroenterol 2003 98 1535 44
24. Gionchetti P Ardizzone S Benvenuti ME et al. A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial Aliment Pharmacol Ther 1999 13 381 8
25. Kane SV Hanauer SB National adherence rates with IBD therapy: PO vs PR Am J Gastroenterol 2001 96 S296
26. Bresci G Parisi G Bertoni M Capria A Long-term maintenance treatment in ulcerative colitis: a 10-year follow-up Dig Liver Dis 2002 34 419 23
27. Han SW McColl E Barton JR et al. Predictors of quality of life in ulcerative colitis: the importance of symptoms and illness representations Inflamm Bowel Dis 2005 11 24 34
28. Janke KH Klump B Gregor M Meisner C Haeuser W Determinants of life satisfaction in inflammatory bowel disease Inflamm Bowel Dis 2005 11 272 86
29. Saibeni S Cortinovis I Beretta L et al. Gender and disease activity influence health-related quality of life in inflammatory bowel diseases Hepatogastroenterology 2005 52 509 15
30. Janke KH Raible A Bauer M et al. Questions on life satisfaction (FLZM) in inflammatory bowel disease Int J Colorectal Dis 2004 19 343 53
31. Brentnall TA Molecular underpinnings of cancer in ulcerative colitis Curr Opin Gastroenterol 2003 19 64 8
32. Moody GA Jayanthi V Probert CS Mac Kay H Mayberry JF Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire Eur J Gastroenterol Hepatol 1996 8 1179 83
33. Eaden J Abrams K Ekbom A Jackson E Mayberry J Colorectal cancer prevention in ulcerative colitis: a case-control study Aliment Pharmacol Ther 2000 14 145 53
34. Pinczowski D Ekbom A Baron J Yuen J Adami HO Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study Gastroenterology 1994 107 117 20
35. van Staa TP Card TR Leufkens HG Logan RF 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study Gut 2005 54 1573 8
36. Velayos FS Terdiman JP Walsh JM Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies Am J Gastroenterol 2005 100 1345 53
37. Aliotta SL Vlasnik JJ Delor B Enhancing adherence to long-term medical therapy: a new approach to assessing and treating patients Adv Ther 2004 21 214 31
38. Dezii CM Medication noncompliance: what is the problem Manag Care 2000 9 Suppl. 7 12
39. Bernstein CN Papineau N Zajaczkowski J et al. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital Am J Gastroenterol 2000 95 677 83
40. Blomqvist P Ekbom A Inflammatory bowel diseases: health care and costs in Sweden in 1994 Scand J Gastroenterol 1997 32 1134 9
41. Hay JW Hay AR Inflammatory bowel disease: costs-of-illness J Clin Gastroenterol 1992 14 309 17
42. Bassi A Dodd S Williamson P Bodger K Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study Gut 2004 53 1471 8
43. Cleemput I Kesteloot K Economic implications of non-compliance in health care Lancet 2002 359 2129 30
44. Bernstein CN Kraut A Blanchard JF et al. The relationship between inflammatory bowel disease and socioeconomic variables Am J Gastroenterol 2001 96 2117 25
45. Longobardi T Jacobs P Wu L Bernstein CN Work losses related to inflammatory bowel disease in Canada: results from a National Population Health Survey Am J Gastroenterol 2003 98 844 9
46. Marri SR Buchman AL The education and employment status of patients with inflammatory bowel diseases Inflamm Bowel Dis 2005 11 171 7
47. Piodi LP Ulivieri FM Cermesoni L Cesana BM Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis Scand J Gastroenterol 2004 39 154 7
48. Haynes RB McKibbon KA Kanani R Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications Lancet 1996 348 383 6
49. Domino FJ Improving adherence to treatment for hypertension Am Fam Physician 2005 71 2089 90
50. Hawkins T Impact of once- and twice-daily dosing regimens on adherence and overall safety AIDS Read 2004 14 34 6
51. Kardas P Comparison of once daily versus twice daily oral nitrates in stable angina pectoris Am J Cardiol 2004 94 213 6
52. Recker RR Gallagher R MacCosbe PE Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women Mayo Clin Proc 2005 80 856 61
53. Kane S Huo D Magnanti K A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis Clin Gastroenterol Hepatol 2003 1 170 3
54. Lichtenstein G Kamm MA Sandborn WJ et al. SPD476 is a novel, once-daily, high-dose, effective and well tolerated 5ASA formulation for the induction of remission of mild-to-moderate ulcerative colitis: a phase III study ACG 2005 100 Suppl. A21
55. Kamm M Sandborn WJ Gassull M et al Comparison of the efficacy and safety of SPD476, a novel, once-daily, high dose formulation of mesalamine, and Asacol with placebo for the induction of remission of mild-moderate ulcerative colitis: a phase III study ACG 2005 100 Suppl. A22
56. Brunner M Greinwald R Kletter K et al. Gastrointestinal transit and release of 5-aminosalicylic acid from 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers Aliment Pharmacol Ther 2003 17 1163 9
57. Wilding I Behrens C Tardif S et al. Combined scintigraphic and pharmacokinetic investigation of enteric-coated mesalazine micropellets in healthy subjects Aliment Pharmacol Ther 2003 17 1153 62
58. Lamet M Ptak T Dallaire C et al. Efficacy and safety of mesalamine 1 g HS versus 500 mg BID suppositories in mild to moderate ulcerative proctitis: a multicenter randomized study Inflamm Bowel Dis 2005 11 625 30
59. Aumais G Lefebvre M Massicotte J et al. Pharmacokinetics and pilot efficacy of a mesalazine rectal gel in distal ulcerative colitis Drugs R D 2005 6 41 6